Title of article
When a new definition overhauls perceptions of MAFLD related cirrhosis care
Author/Authors
zheng, kenneth i. wenzhou medical university - mafld research center, the first affiliated hospital - department of hepatology, Wenzhou, China , eslam, mohammed university of sydney - storr liver centre, westmead institute for medical research, westmead hospital, Sydney, Australia , george, jacob university of sydney - storrliver centre, westmead institute for medical research, westmead hospital, Sydney, Australia , zheng, ming-hua university of sydney - storrliver centre, westmead institute for medical research, westmead hospital, Sydney, Australia , zheng, ming-hua wenzhou medical university - institute of hepatology, Wenzhou, china , zheng, ming-hua wenzhou medical university - mafld research center, the first affiliated hospital - department of hepatology, Wenzhou, China , zheng, ming-hua key laboratory of diagnosis and treatment for the development of chronic liver disease in zhejiang province, Wenzhou, China
From page
801
To page
804
Abstract
Editorial: Metabolic-associated fatty liver disease (MAFLD) (1), formerly known as non-alcoholic fatty liver disease, is a major causes of liver cirrhosis (2). MAFLD represents a growing global health and economic burden since approximately one in four people have the disease (3). As a consequence, MAFLD-related cirrhosis is expected to become the leading cause for liver failure and liver cancer, and the major indication for liver transplantation this century (3).
Journal title
Hepatobiliary Surgery and Nutrition
Journal title
Hepatobiliary Surgery and Nutrition
Record number
2655341
Link To Document